Evolus (NASDAQ:EOLS) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Evolus (NASDAQ:EOLS) in a research report report published on Monday, Benzinga reports.

A number of other research firms have also commented on EOLS. HC Wainwright reiterated a buy rating and set a $27.00 price target on shares of Evolus in a report on Thursday, August 1st. Needham & Company LLC restated a buy rating and issued a $22.00 price objective on shares of Evolus in a research report on Thursday, August 1st.

Evolus Stock Performance

NASDAQ:EOLS opened at $15.09 on Monday. The business has a 50 day moving average of $13.34 and a 200 day moving average of $12.99. The company has a market capitalization of $952.03 million, a price-to-earnings ratio of -14.37 and a beta of 1.30. Evolus has a 1-year low of $7.44 and a 1-year high of $16.29. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67.

Evolus (NASDAQ:EOLS) last released its earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The company had revenue of $66.91 million during the quarter, compared to the consensus estimate of $65.06 million. On average, sell-side analysts predict that Evolus will post -0.64 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at $2,224,559.96. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the transaction, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Evolus

Several large investors have recently modified their holdings of the stock. Perceptive Advisors LLC increased its stake in Evolus by 166.8% during the 4th quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock valued at $41,735,000 after purchasing an additional 2,477,623 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of Evolus by 5,627.2% during the second quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock valued at $10,276,000 after acquiring an additional 930,566 shares in the last quarter. Lord Abbett & CO. LLC purchased a new position in Evolus in the 1st quarter worth approximately $11,628,000. BNP Paribas Financial Markets lifted its position in Evolus by 84.2% in the 1st quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock valued at $5,683,000 after acquiring an additional 185,532 shares in the last quarter. Finally, Armistice Capital LLC purchased a new stake in Evolus during the 2nd quarter valued at $3,906,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.